Cart
sales@molnova.com
Nidanilimab
CAS No. 2171061-85-9
Nidanilimab( —— )
Catalog No. M36753 CAS No. 2171061-85-9
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 715 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1663 | In Stock |
|
| 50MG | 2186 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNidanilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells.
-
DescriptionNidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
-
In Vitro——
-
In VivoAnimal Model:Nude C57Bl/6 mice with LU2503 NSCLC PDX model Dosage:10 mg/kg Administration:Intraperitoneal injection Result:Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2171061-85-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
molnova catalog
related products
-
Daclizumab
Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.
-
Cyclosporin D
Cyclosporin D is a metabolite of cyclosporin A, an immunosuppressant drug that binds cyclophilin D, inhibiting the phosphatase activity of calcineurin in T cells.
-
Caulophyllogenin
Caulophyllogenin is a partial PPARγ agonist (EC50?=?12.6?μM) derived from the stem bark of Kalopanax pictus (Araliaceae).
